Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, ERAS, IDYA, TERN, PRAX, and represent 34.31% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: CNTA (+$77M), TERN (+$66M), UTHR (+$47M), MDGL (+$45M), CYTK (+$38M), ABVX (+$31M), ELVN (+$27M), XENE (+$26M), CGON (+$25M), TYRA (+$25M).
- Started 11 new stock positions in SNSE, AVTX, ALKS, Veradermics, AVBP, XENE, TENX, MDGL, MGTX, UTHR. RLAY.
- Reduced shares in these 10 stocks: RVMD (-$97M), CDTX (-$69M), Avidity Biosciences Ord (-$36M), , ERAS (-$30M), PRAX (-$29M), APLS (-$25M), TNGX (-$25M), PCVX (-$20M), QURE (-$16M).
- Sold out of its positions in APLS, ACLX, Avidity Biosciences Ord, CDTX, DBVT, DAWN, KYMR, MREO, NGNE, NRIX. NUVB.WS, JAZZ, KNSA, IMTX, QURE.
- Logos Global Management was a net buyer of stock by $97M.
- Logos Global Management has $2.0B in assets under management (AUM), dropping by 21.03%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Logos Global Management
Logos Global Management holds 63 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 9.7 | $195M | -33% | 2.0M | 97.25 |
|
| Erasca (ERAS) | 9.0 | $180M | -14% | 11M | 16.18 |
|
| Ideaya Biosciences (IDYA) | 5.7 | $115M | -3% | 3.5M | 33.32 |
|
| Terns Pharmaceuticals (TERN) | 5.3 | $105M | +166% | 2.0M | 52.72 |
|
| Praxis Precision Medicines I Com New (PRAX) | 4.6 | $92M | -24% | 285k | 322.19 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 4.2 | $84M | +962% | 2.1M | 39.72 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.8 | $75M | +68% | 675k | 111.35 |
|
| Tango Therapeutics (TNGX) | 3.1 | $63M | -28% | 3.0M | 20.92 |
|
| Cytokinetics Com New (CYTK) | 2.9 | $58M | +191% | 875k | 65.91 |
|
| Olema Pharmaceuticals (OLMA) | 2.4 | $48M | 3.2M | 14.91 |
|
|
| United Therapeutics Corporation (UTHR) | 2.4 | $47M | NEW | 80k | 592.98 |
|
| Immunocore Hldgs Ads (IMCR) | 2.3 | $45M | +76% | 1.5M | 30.15 |
|
| Madrigal Pharmaceuticals (MDGL) | 2.2 | $45M | NEW | 85k | 523.47 |
|
| Enliven Therapeutics (ELVN) | 2.0 | $41M | +205% | 1.0M | 39.20 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.0 | $39M | +136% | 450k | 86.97 |
|
| Cg Oncology (CGON) | 1.9 | $39M | +187% | 575k | 67.68 |
|
| Maze Therapeatics (MAZE) | 1.8 | $37M | +30% | 1.2M | 29.85 |
|
| Biogen Idec (BIIB) | 1.8 | $37M | 200k | 183.33 |
|
|
| Disc Medicine (IRON) | 1.8 | $36M | +9% | 560k | 63.94 |
|
| Dianthus Therapeutics (DNTH) | 1.7 | $34M | +26% | 400k | 83.92 |
|
| Ocular Therapeutix (OCUL) | 1.6 | $33M | +10% | 3.9M | 8.47 |
|
| Tyra Biosciences (TYRA) | 1.6 | $33M | +304% | 850k | 38.30 |
|
| Trevi Therapeutics (TRVI) | 1.4 | $29M | +54% | 2.4M | 11.93 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.4 | $28M | -14% | 1.5M | 18.64 |
|
| Immunovant (IMVT) | 1.3 | $27M | -21% | 1.1M | 24.84 |
|
| Xenon Pharmaceuticals (XENE) | 1.3 | $26M | NEW | 450k | 58.15 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.3 | $26M | +14% | 1.2M | 21.60 |
|
| Dyne Therapeutics (DYN) | 1.3 | $25M | +12% | 1.4M | 18.13 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.2 | $24M | -16% | 500k | 48.20 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 1.1 | $23M | -23% | 915k | 24.66 |
|
| Design Therapeutics (DSGN) | 1.0 | $21M | -22% | 2.0M | 10.64 |
|
| Avalo Therapeutics Com New (AVTX) | 1.0 | $19M | NEW | 1.3M | 14.93 |
|
| Minerva Neurosciences Com New (NERV) | 1.0 | $19M | -2% | 3.2M | 6.03 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $19M | +33% | 600k | 32.01 |
|
| Mirum Pharmaceuticals (MIRM) | 0.9 | $19M | -11% | 200k | 92.38 |
|
| Vaxcyte (PCVX) | 0.9 | $17M | -53% | 300k | 58.11 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.8 | $17M | -11% | 750k | 22.26 |
|
| Compass Therapeutics (CMPX) | 0.8 | $17M | +173% | 3.2M | 5.29 |
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $14M | +28% | 450k | 31.72 |
|
| Janux Therapeutics (JANX) | 0.7 | $14M | 1.0M | 13.90 |
|
|
| Vor Biopharma Com New (VOR) | 0.7 | $13M | +650% | 750k | 17.84 |
|
| Alkermes SHS (ALKS) | 0.6 | $12M | NEW | 350k | 35.36 |
|
| Oric Pharmaceuticals (ORIC) | 0.6 | $12M | +111% | 950k | 12.67 |
|
| Immix Biopharma (IMMX) | 0.6 | $11M | +22% | 1.2M | 9.11 |
|
| Tenax Therapeutics Com New (TENX) | 0.5 | $10M | NEW | 625k | 15.99 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.5 | $9.7M | -26% | 700k | 13.90 |
|
| Crescent Biopharma (CBIO) | 0.4 | $8.9M | -19% | 483k | 18.37 |
|
| Soleno Therapeutics (SLNO) | 0.4 | $8.4M | -16% | 250k | 33.48 |
|
| Arrivent Biopharma (AVBP) | 0.4 | $8.1M | NEW | 350k | 23.07 |
|
| Relay Therapeutics (RLAY) | 0.4 | $7.5M | NEW | 750k | 9.95 |
|
| Corvus Pharmaceuticals (CRVS) | 0.3 | $6.6M | -10% | 450k | 14.63 |
|
| Meiragtx Holdings (MGTX) | 0.3 | $6.1M | NEW | 700k | 8.66 |
|
| Jade Biosciences Com New (JBIO) | 0.3 | $5.6M | 400k | 14.05 |
|
|
| Verastem Com New (VSTM) | 0.3 | $5.3M | -41% | 1.0M | 5.30 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.2 | $3.1M | 474k | 6.58 |
|
|
| Ibio Com New (IBIO) | 0.1 | $2.5M | -35% | 1.3M | 1.90 |
|
| Palatin Technologies Com New (PTN) | 0.1 | $2.4M | 140k | 17.42 |
|
|
| Aclaris Therapeutics (ACRS) | 0.1 | $1.9M | -16% | 500k | 3.75 |
|
| Pharvaris N V (PHVS) | 0.1 | $1.8M | -35% | 65k | 28.25 |
|
| Veradermics Common Stock | 0.1 | $1.6M | NEW | 25k | 63.15 |
|
| Sensei Biotherapeutics Com New (SNSE) | 0.0 | $946k | NEW | 30k | 31.52 |
|
| Septerna (SEPN) | 0.0 | $566k | 24k | 24.03 |
|
|
| Fractyl Health (GUTS) | 0.0 | $458k | -9% | 1.0M | 0.46 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2026 Q1 filed May 15, 2026
- Logos Global Management 2025 Q4 filed Feb. 17, 2026
- Logos Global Management 2025 Q3 filed Nov. 14, 2025
- Logos Global Management 2025 Q2 filed Aug. 14, 2025
- Logos Global Management 2025 Q1 filed May 15, 2025
- Logos Global Management 2024 Q4 filed Feb. 14, 2025
- Logos Global Management 2024 Q3 filed Nov. 14, 2024
- Logos Global Management 2024 Q2 amended filed Aug. 27, 2024
- Logos Global Management 2024 Q2 filed Aug. 14, 2024
- Logos Global Management 2024 Q1 filed May 15, 2024
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023
- Logos Global Management 2022 Q3 filed Nov. 14, 2022